Company intelligence / Profile preview
Ferryx
Bristol, England, United Kingdomferryx.com ↗
- Ownership
- Private
- Employees
- ~3
- Development stage
- Commercial
01
Overview
Ferryx has launched its first commercial product, Ferrocalm, containing the FX856 bacterial strain to address gut inflammation and IBS symptoms. Early user results are positive. A clinical trial in IBD patients with FX856 was being planned as of late 2022.
- Therapeutic areas
- GastroenterologyOther
- Modalities
- Live biotherapeutic products (probiotics)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Ferryx.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ferryx.